CRISPR ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

阿斯利康（AstraZeneca PLC）于周三宣布，其最新试验评估的Enhertu在高风险、局部晚期HER2阳性早期乳腺癌患者中获得了积极的高水平结果。该公司表示，Destiny-Breast11三期试验显示，Enhertu（trastuzumab deruxtecan）联合使用紫杉醇、曲妥珠单抗和帕妥珠单抗，较现行标准治疗在病理完全缓解率上实现了统计学和临床上显著的改善。 Enhertu由阿斯 ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed ...

Drugmaker AstraZeneca revealed on Wednesday that it had received "positive high-level results" from a Phase III trial on its ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

ENHERTU is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...

Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.